| Ytd | 43.31% | |
| 1y | 70.59% |
| Open | 23.61 | Prev Close | 23.83 | Low | 23.43 | High | 24.05 | Mkt Cap | 3.78B |
| Vol | 328.52K | Avg Vol | 1.92M | EPS | -2.88 | P/E | -8.27 | Forward P/E | -10.98 |
| Beta | 0.96 | Short Ratio | 8.17 | Inst. Own | 105.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 22.18 | 200-d Avg | 19.51 | 1yr Est | 33.93 |
DNLI News
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fr
JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partners
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to adv
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVL
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt d
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through s
Denali Therapeutics NASDAQ: DNLI is seeing early commercial interest for its first approved drug, AV
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transc
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatme
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI
This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinic
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fun
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agree
Capricorn Fund Managers Ltd acquired a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the f
SG Americas Securities LLC boosted its holdings in Denali Therapeutics Inc. (NASDAQ: DNLI) by 291.6%
Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualco
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday